GIMAP6 has been recognized as a prognostic biomarker in head and neck squamous cell carcinoma, breast cancer, and female lung adenocarcinoma and as a predictor of response to immunotherapy in lung adenocarcinoma (64–66). This evidence concerns the gene GIMAP6 and breast carcinoma.